Compare RVT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVT | MLYS |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | N/A | 2023 |
| Metric | RVT | MLYS |
|---|---|---|
| Price | $16.41 | $23.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 224.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 2.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.12 | $10.44 |
| 52 Week High | $18.73 | $47.65 |
| Indicator | RVT | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 37.39 |
| Support Level | $15.77 | $12.98 |
| Resistance Level | $16.50 | $31.09 |
| Average True Range (ATR) | 0.45 | 1.60 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 25.00 | 16.78 |
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements. The company invests in Industrials, Financials, Information Technology, Materials, Health Care, Communication Services, Real Estate and others.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.